BRIEF-Celcuity’s Phase 3 VIKTORIA-2 Trial of Gedatolisib as a First-Line Treatment for HR+/HER2- Advanced Breast Cancer Expanding to Include Endocrine-Sensitive Patients

Celcuity Inc.

Celcuity Inc.

CELC

0.00

May 14 (Reuters) - Celcuity Inc CELC.O:

  • CELCUITY’S PHASE 3 VIKTORIA-2 TRIAL OF GEDATOLISIB AS A FIRST-LINE TREATMENT FOR HR+/HER2- ADVANCED BREAST CANCER EXPANDING TO INCLUDE ENDOCRINE-SENSITIVE PATIENTS

  • CELCUITY INC - VIKTORIA-2 TRIAL EXPANDS TO INCLUDE ENDOCRINE-SENSITIVE HR+/HER2- ADVANCED BREAST CANCER PATIENTS

  • CELCUITY INC - HOLDS TYPE B MEETING WITH FDA ON AMENDED PHASE 3 TRIAL DESIGN

  • CELCUITY INC - FDA GRANTS PRIORITY REVIEW TO CELCUITY'S NDA FOR GEDATOLISIB WITH PDUFA DATE JULY 17, 2026

  • CELCUITY INC - SUBMITS PATENT APPLICATION FOR SUBCUTANEOUS FORMULATION OF GEDATOLISIB

Source text: ID:nGNXXDcnS

Further company coverage: CELC.O


This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.